组蛋白甲基转移酶EZH2调控脓毒症诱导T细胞功能障碍的作用及分子机制
该研究将24只雄性C57BL/6小鼠随机分为假手术组、脓毒症模型组(CLP+DMSO)和EZH2选择性抑制剂组(CLP+GSK126),每组8只,术后即刻分别腹腔注射DMSO或GSK126(10 mg/kg),24小时后处死取肠系膜淋巴结行流式检测。结果显示,与CLP+DMSO组相比,CLP+GSK126组CD3+ T细胞比例升高(0.70±0.02 vs. 0.50±0.07,P<0.01),CD4+和CD8+ T细胞中ki-67+细胞比例升高(CD4+:0.74±0.05 vs. 0.63±0.04;CD8+:0.82±0.06 vs. 0.70±0.04,均P<0.05),IFN-γ+CD4+和IFN-γ+CD8+ T细胞比例升高(IFN-γ+CD4+:0.31±0.11 vs. 0.14±0.06;IFN-γ+CD8+:0.30±0.10 vs. 0.13±0.06,均P<0.05),CD8+ T细胞PD-1+细胞比例下调(0.092±0.006 vs. 0.135±0.004,P<0.01)。两组CD4+和CD8+ T细胞凋亡率无显著差异(CD4+:(21.53±2.87)% vs.(20.48±3.21)%;CD8+:(8.34±1.02)% vs.(7.71±1.38)%,均P>0.05),PD-L1+细胞无显著变化。作者认为EZH2可能通过调控PD-1表达参与脓毒症
要点
- CLP脓毒症小鼠术后即刻腹腔注射GSK126(10 mg/kg),24小时后肠系膜淋巴结CD3+ T细胞比例较CLP+DMSO组升高(0.70±0.02 vs. 0.50±0.07,P<0.01)。
- GSK126组CD4+和CD8+ T细胞中ki-67+细胞比例均较CLP+DMSO组升高(CD4+:0.74±0.05 vs. 0.63±0.04;CD8+:0.82±0.06 vs. 0.70±0.04,均P<0.05)。
- GSK126组IFN-γ+CD4+和IFN-γ+CD8+ T细胞比例均较CLP+DMSO组升高(0.31±0.11 vs. 0.14±0.06;0.30±0.10 vs. 0.13±0.06,均P<0.05)。
- GSK126组CD8+ T细胞PD-1+细胞比例较CLP+DMSO组下调(0.092±0.006 vs. 0.135±0.004,P<0.01),PD-L1+细胞无显著变化。
- GSK126组与CLP+DMSO组CD4+和CD8+ T细胞凋亡率均无显著差异(CD4+:(21.53±2.87)% vs.(20.48±3.21)%;CD8+:(8.34±1.02)% vs.(7.71±1.38)%,均P>0.05)。
适用人群与场景
- 雄性C57BL/6小鼠,共24只,随机分为假手术组、脓毒症模型组(CLP+DMSO组)和EZH2选择性抑制剂组(CLP+GSK126组),每组8只。
处置流程与药物剂量
- 脓毒症小鼠模型采用盲肠结扎穿孔术(CLP)复制。
- CLP+DMSO组和CLP+GSK126组分别于术后即刻腹腔注射DMSO或GSK126(10 mg/kg)。
- 术后24小时处死小鼠,取肠系膜淋巴结,用流式细胞术检测EZH2表达、凋亡率、ki-67+细胞、IFN-γ+细胞、PD-1+细胞和PD-L1+细胞。
研究设计与关键结果
- 研究类型为动物实验;24只雄性C57BL/6小鼠随机分为假手术组、CLP+DMSO组和CLP+GSK126组,每组8只。
- 与假手术组比较,CLP+DMSO组肠系膜淋巴结T淋巴细胞EZH2表达上调。
- 与CLP+DMSO组比较,CLP+GSK126组CD3+ T淋巴细胞比例升高(0.70±0.02 vs. 0.50±0.07,P<0.01)。
- 与CLP+DMSO组比较,CLP+GSK126组CD4+和CD8+ T淋巴细胞中ki-67+细胞比例升高(CD4+:0.74±0.05 vs. 0.63±0.04;CD8+:0.82±0.06 vs. 0.70±0.04,均P<0.05)。
- CLP+GSK126组与CLP+DMSO组CD4+和CD8+ T淋巴细胞凋亡率无显著差异(CD4+:(21.53±2.87)% vs.(20.48±3.21)%;CD8+:(8.34±1.02)% vs.(7.71±1.38)%,均P>0.05)。
- 与CLP+DMSO组比较,CLP+GSK126组IFN-γ+CD4+和IFN-γ+CD8+ T淋巴细胞比例升高(IFN-γ+CD4+:0.31±0.11 vs. 0.14±0.06;IFN-γ+CD8+:0.30±0.10 vs. 0.13±0.06,均P<0.05)。
- 与CLP+DMSO组比较,CLP+GSK126组CD8+ T淋巴细胞中PD-1+细胞比例下调(0.092±0.006 vs. 0.135±0.004,P<0.01),PD-L1+细胞无显著变化。
证据类型、等级与局限
- 证据类型:动物实验(小鼠CLP脓毒症模型)。
- 作者结论:EZH2可能通过调控PD-1表达参与脓毒症诱导的T淋巴细胞功能障碍。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究为小鼠CLP脓毒症模型实验,原文结论为EZH2可能通过调控PD-1表达参与脓毒症诱导的T淋巴细胞功能障碍,未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effect and mechanism of histone methyltransferase enhancer of zeste homolog 2 (EZH2) on sepsis-induced T cell dysfunction.
METHODS: Twenty-four male C57BL/6 mice were divided into three groups randomly: sham operated group, sepsis model group [cecum ligation and puncture (CLP)+dimethyl sulfoxide (DMSO) group] and EZH2 selective inhibitor treated group (CLP+GSK126 group), with 8 mice in each group. Sepsis murine model was reproduced by CLP. CLP+DMSO group and CLP+GSK126 group were treated with DMSO or GSK126 (10 mg/kg) respectively right after surgery through intraperitoneal injection. The mice were sacrificed 24 hours after operation, and the mesenteric lymph nodes were collected. The expression of EZH2, apoptosis rates, cell proliferation marker ki-67 antigen positive T lymphocytes (ki-67+ cell), interferon-γ positive T lymphocytes (IFN-γ + cell), programmed death receptor-1 positive T lymphocytes (PD-1+ cell) and programmed death-ligand 1 positive T lymphocytes (PD-L1+ cell) were determined by flow cytometry.
RESULTS: Compared with sham operated group, the expression of EZH2 in T lymphocytes was up-regulated on mesenteric lymph nodes of CLP+DMSO group. Compared with CLP+DMSO group, the ratio of CD3+ T lymphocytes in CLP+GSK126 group was up-regulated (0.70±0.02 vs. 0.50±0.07, P < 0.01), indicating that the EZH2 inhibitor could increase the number of T lymphocytes in lymph nodes of septic mice; the ratio of ki-67+ cells in CD4+ and CD8+ T lymphocytes in CLP+GSK126 group was increased (CD4+: 0.74±0.05 vs. 0.63±0.04, CD8+: 0.82±0.06 vs. 0.70±0.04, both P < 0.05), indicating that the EZH2 inhibitor could increase the ratio of T lymphocytes with high proliferative activity in lymph nodes of septic mice. However, no significant difference was found on both CD4+ and CD8+ T lymphocytes apoptosis rates in the mesenteric lymph nodes of mice between CLP+GSK126 group and CLP+DMSO group [CD4+: (21.53±2.87)% vs. (20.48±3.21)%, CD8+: (8.34±1.02)% vs. (7.71±1.38)%, both P > 0.05], indicating that no extra T lymphocytes apoptosis was induced by EZH2 inhibitor. Compared with CLP+DMSO group, the ratios of IFN-γ + CD4+ and IFN-γ + CD8+ T lymphocytes were increased in CLP+GSK126 group (IFN-γ +CD4+: 0.31±0.11 vs. 0.14±0.06, IFN-γ +CD8+: 0.30±0.10 vs. 0.13±0.06, both P < 0.05), suggesting that secretion of IFN-γ in lymph nodes by sepsis T lymphocytes was augmented after EZH2 inhibitor administration. Furthermore, compared with CLP+DMSO group, the ratio of PD-1+ cell in CD8+ T lymphocyte was down-regulated in CLP+GSK126 group (0.092±0.006 vs. 0.135±0.004, P < 0.01), suggesting that EZH2 inhibitor restrained the PD-1 expression on sepsis lymphoid node CD8+ T lymphocytes, however, it had no significant effect on PD-L1+ cells.
CONCLUSIONS: EZH2, regulates sepsis-induced T lymphocyte dysfunction, possibly through modulating the expression of PD-1.
参考来源
- Li Z, Zhao D, Zhou X, et al. [Effects and molecular mechanism of histone methyltransferase enhancer of zeste homolog 2 on regulating sepsis-induced T cell dysfunction]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35692198. doi:10.3760/cma.j.cn121430-20210906-01323
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。